Meibomian Gland Dysfunction Market: Size and Share Analysis, Recent Developmental Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast Till 2030

June 29 04:50 2021
Meibomian Gland Dysfunction Market: Size and Share Analysis, Recent Developmental Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast Till 2030

Delveinsight Business Research LLP

DelveInsight’s “Meibomian Gland Dysfunction Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Meibomian Gland Dysfunction Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Meibomian glands are the tiny oil glands present on the margin of the eyelids (the edges which touch when the eyelids are closed). These glands secrete oil that coats the surface of our eyes and keeps the water component of our tears from evaporating (drying out).

Treatments for Meibomian gland dysfunction typically include applying warm compresses to the eyelids, followed by massaging the eyelids. The goal of this treatment was to melt and express any thickened oil clogging the openings of Meibomian glands. However, several new treatment options are present now such as The LipiFlow thermal pulsation system, iLUX, TearCare, Intense pulsed light (IPL), Blephex, Lid debridement, Antibacterial and Cyclosporin eye drops, and the Omega-3 supplements.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/meibomian-gland-dysfunction-market

The Meibomian Gland Dysfunction Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Meibomian Gland Dysfunction market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Meibomian Gland Dysfunction treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Meibomian Gland Dysfunction Market

Meibomian Gland Dysfunction Market Key Facts

  • As per the study titled “Global Prevalence of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis” conducted by Hassanzadeh et al., 2020, MGD is quite a prevalent disorder with an estimated pooled prevalence of 35.8%. Men are more prone to MGD than women. The rate of MGD was between 21.2% and 29.5% in Africans and Caucasians, to 71.0% in Arabs, and 67.5% in Hispanics.

  • As per DelveInsight, the Meibomian Gland Dysfunction is more common in males than in females in the 7MM. 

  • A study titled “Eyelid Disorders in Ophthalmology Practice: Results from a Large International Epidemiological Study in Eleven Countries”, July 2020, was conducted on 6660 patients. Data from 6525 patients were used in the final analysis & it concluded that Population-based epidemiologic studies have reported prevalence of dry eye up to 34% based on geographic locale. This study confirms a high prevalence of dry eye, MGD, and associated ocular surface disorders in a population of patients.

Key Benefits of Meibomian Gland Dysfunction Market Report

  • Meibomian Gland Dysfunction market report provides an in-depth analysis of Meibomian Gland Dysfunction Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Meibomian Gland Dysfunction Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Meibomian Gland Dysfunction current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Meibomian Gland Dysfunction market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Meibomian Gland Dysfunction Market

Meibomian Gland Dysfunction market size is anticipated to increase during the study period owing to the increasing prevalent population and awareness of MGD patients in the 7MM. Along with these, the development of advanced technologies will also give robust growth to the market.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Meibomian Gland Dysfunction market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

 The report gives a thorough detail of the Meibomian Gland Dysfunction market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

Meibomian Gland Dysfunction Epidemiology

The epidemiology section covers insights about the historical and current Meibomian Gland Dysfunction patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Meibomian Gland Dysfunction Epidemiology Segmentation

  • Total Prevalent Pool of MGD

  • Gender-specific Prevalent Pool of MGD

  • Age-specific Prevalent Pool of MGD

  • Clinical Subtype-based (Typical/Atypical) Diagnosed Prevalent Pool of MGD

Meibomian Gland Dysfunction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Meibomian Gland Dysfunction market or expected to get launched in the market during the study period. The analysis covers Meibomian Gland Dysfunction market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Meibomian Gland Dysfunction Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Meibomian Gland Dysfunction market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Meibomian Gland Dysfunction emerging therapies.

Several promising pharmacologic therapies are currently being evaluated, and with the renewed interest in MGD, the future is bright for new therapeutic options. There is still an unmet need for better treatments for MGD, and the novel products are undoubtedly going to address the shortcomings of existing options.

At present, various Pharmaceutical companies are conducting late-stage clinical trials for MGD. Many companies are also developing several lipid modulators and medical devices for relieving the symptoms of meibomian gland dysfunction.

Some of the key companies in the Meibomian Gland Dysfunction market include – 

  • Azura Ophthalmics

  • Bausch Health Americas, Inc. 

  • Hovione Scientia Limited

And others

Meibomian Gland Dysfunction Therapies covered in the report include:

  • NOV03

  • AZR-MD-001

  • Topical Minocycline Ointment

And many more. 

As per the DelveInsight, the overall dynamics of the Meibomian Gland Dysfunction market is anticipated to change in the coming years owing to the expected launch of Targeted therapies.

Table of Content

1. Key Insights

2. Executive Summary 

3. Meibomian Gland Dysfunction Competitive Intelligence Analysis

4. Meibomian Gland Dysfunction Market Overview at a Glance

5. Meibomian Gland Dysfunction Disease Background and Overview

6. Meibomian Gland Dysfunction Patient Journey

7. Meibomian Gland Dysfunction Epidemiology and Patient Population

8. Meibomian Gland Dysfunction Treatment Algorithm, Current Treatment, and Medical Practices

9. Meibomian Gland Dysfunction Unmet Needs

10. Key Endpoints of Meibomian Gland Dysfunction Treatment

11. Meibomian Gland Dysfunction Marketed Products

12. Meibomian Gland Dysfunction Emerging Therapies

13. Meibomian Gland Dysfunction Seven Major Market Analysis

14. Attribute Analysis

15. Meibomian Gland Dysfunction Market Outlook (7 major markets)

16. Meibomian Gland Dysfunction Access and Reimbursement Overview

17. KOL Views on the Meibomian Gland Dysfunction Market.

18. Meibomian Gland Dysfunction Market Drivers

19. Meibomian Gland Dysfunction Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/meibomian-gland-dysfunction-market

Latest Reports By DelveInsight
Meibomian Gland Dysfunction Pipeline Insights
Meibomian Gland Dysfunction Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Meibomian Gland Dysfunction Market.

Insulin Resistance Market
DelveInsight’s “Insulin Resistance Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Insulin Resistance market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author